Skip to content
Buy This GLP
← Research
Evidence

How Long Do People Stay on a GLP-1? About a Third Reach One Year

In obesity cohorts without diabetes, roughly one in three are still taking it at twelve months. Some advertised rates require a longer commitment and an upfront payment.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read

About a third reach twelve months. In obesity cohorts without diabetes, roughly one in three are still on therapy at one year. Among people with type 2 diabetes, nearly half have stopped by twelve months and about seventy percent by twenty-four [1]. These estimates vary by study population and how researchers define stopping treatment.

Studies define discontinuation differently. The analysis of refill gaps explains how the number of days without a refill changes who counts as having stopped. Patients also stopped in a clinic program that provided treatment at no cost. That study describes what happened in one program and does not isolate the effect of price.

A review of real-world studies estimates that about one third of patients in obesity cohorts without diabetes remain on treatment at one year. In cohorts with type 2 diabetes, nearly half stop by 12 months and about 70% by 24 months [1]. Use the monthly cost guide to compare the price of refills with the cost of committing to a longer plan.

What a longer plan costs upfront

The GLP-1 price rankings show comparable monthly figures and note the terms behind the prices. In the catalog, injectable semaglutide ranges from $60 to $1,299 a month. For a prepaid offer, check the total due and how much medication that payment covers.

What the persistence figures do and do not say

These are real-world claims and cohort data, not trial results, and they measure something the trials cannot: what people do when nobody is calling them for a study visit. The commentary behind those figures proposes using pharmacy claims to spot the early warning signs of discontinuation, and the signs it names are worth reading as a buyer rather than as a payer. Delayed refills. Prolonged use of starter doses. High out-of-pocket costs, and patterns of gastrointestinal adverse effects [1].

Wartko and colleagues studied 335,605 adults with type 2 diabetes and obesity enrolled in private or Medicare Advantage plans. The cohort included people who started a GLP-1 receptor agonist or SGLT2 inhibitor, or had bariatric surgery. Among GLP-1 starters, 53.0% were still using the treatment they started at one year [3].

The one-third estimate comes from obesity cohorts without diabetes. The insured cohort had both diabetes and obesity, so the figures describe different populations. The analysis of treatment persistence among insured patients describes how the researchers used prescription claims to track refills. Among people in that insured cohort who started an SGLT2 inhibitor, 56.0% remained on their initial treatment at one year [3].

Two of those four are about money. High out-of-pocket cost is itself a predictor of stopping, which means the annual prepay sits on both sides of the equation: it lowers the monthly figure and raises the amount at risk.

Cost is itself a reason people stop

A retrospective real-world cohort of adults with overweight or obesity and no diabetes (n = 248, mean age 55.0 years, mean BMI 34.8 kg/m², 77.5 percent female) recorded why people came off semaglutide. Discontinuation due to non-severe gastrointestinal adverse events was 10.4 percent, and discontinuation due to cost was 5.7 percent[2]. The authors describe persistence in the cohort as low and call for structured support to improve it.

Those percentages describe reasons recorded in one clinic cohort. They do not predict why an individual patient will stop treatment.

The measurement nobody has made

The cited studies did not measure whether paying for a year upfront changes how long people stay on treatment. Use the contract terms to estimate how much you could lose if you stop before the end of a prepaid plan.

What to actually do

Before paying for a longer term, use the guide to prepaid GLP-1 plans to compare the full upfront cost with the cost of paying as you go. Check whether unused months are refundable and whether a higher dose would change your bill. The review of higher-dose pricing shows why the starting price alone may leave that question open.

With both quotes in hand, use the GLP-1 cost calculator to compare the same medication and treatment period. Include fees and use the stated billing interval for each quote.

Price figures above are computed from this site’s own records at build time, most recently read November 2026. The persistence figures are cited and are not this site’s own.

Frequently asked

How many people are still taking a GLP-1 after a year?
In obesity cohorts without diabetes, approximately one third remain on therapy at one year. Among people with type 2 diabetes, nearly half discontinue by twelve months and around seventy percent by twenty-four. In a large insured cohort of adults with both type 2 diabetes and obesity, 53.0% of GLP-1 starters were still using the drug at one year.
Does prepaying a year improve the odds of finishing it?
The studies cited here did not compare people by payment term. The cost of stopping early depends on the refund and cancellation terms.
Is an annual discount a bad deal?
Not automatically. It is a real saving on a real risk. It becomes a problem when the annual rate is presented on a product card as though it were the monthly price.

Sources

  1. [1] Sisodia A, et al. (2026). Predicting GLP-1 Discontinuation From Pharmacy Claims The American Journal of Managed Care. PMID 42663544
  2. [2] Milani I, et al. (2026). Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment Frontiers in Endocrinology. PMID 42582375
  3. [3] Wartko PD, et al. (2026). Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity Diabetes Research and Clinical Practice. PMID 42624330

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence